


Monopar Therapeutics (MNPR)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001645469

Monopar Therapeutics			Share price, twelve months to the rescansplit-adjusted close; the letter is fixed at the rescans that set it 		
Grade	None	5 of 14 inputs computable; 7 are required			
Reliability	0.87 AUC	filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025			
Peer failure rate	1.03% a year	Item 1.03 bankruptcies, same asset band, 2012 to 2025			
Size band	\$120M to \$591M assets	total assets \$140.7M			
Standard universe	outside	revenue above \$1M and assets above \$10M			
Warnings	thin data, degenerate inputs	not computable: distress, fortress balance sheet			
Inputs computable	5 of 14				
Graded from	filings received through Apr 1, 2026	191 days before the rescans; latest periodic filing 10-Q received Aug 12, 2026			
Last close	\$84.74	2026-10-08; market equity \$568.8M			
Price used in grade	None				

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 27, 2026

- License, Development and Collaboration Agreements." Pursuant to the terms of our license agreement with AstraZeneca for ALXN1840, we obtained the intellectual property portfolio for ALXN1840, including exclusive license and prosecution of over 86 patent applications granted, published, or pending in over 30 countries worldwide. ALXN1840 has been granted Orphan Drug Designation for the treatment of Wilson disease in the U.S. and the EU, as well as Fast Track designation from the FDA. In the U.S., these include 6 granted patents, 7 published patent applications, and 1 private and pending application with the earliest expiration expected in 2038.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 78.0						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(1.5%)	(6.6%)	78.0	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 0.2						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		53.62	(0.31)	0.3	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		51.35x	2.96x	0.1	839	2025-12-31
Growth and financing, sleeve percentile 26.1						
Revenue growth, three-year compound		not computable	10.0%			four consecutive annual observations are required
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 0
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		119.9%	2.1%	1.6	704	2025-12-31
Net share issuance, one year		9.5%	2.5%	50.7	634	2026-03-17

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	5 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	37.1%	8.0%	70

Distance from 52-week high	(32.2%)	(31.4%)	48
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	0.23	0.28	46
Sales to price	0.00	0.31	0
Composite equity issuance, five years	98.2%	20.3%	77
Relative strength against the sector, log excess return	0.10	(0.14)	70

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$52.8M
Operating cash flow, four quarters	-\$12.2M
Months of runway	52.0
Days since last periodic filing	58 (10-Q received Aug 12, 2026)
Median daily dollar volume, 63 sessions	\$21.0M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$13.7M	2025-12-31	2026-03-27	10-K	0001437749-26-010025
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$12.2M	2025-12-31	2026-03-27	10-K	0001437749-26-010025
3	assets	us-gaap:Assets	\$140.7M	2025-12-31	2026-03-27	10-K	0001437749-26-010025
4	assets	us-gaap:Assets	\$60.3M	2024-12-31	2026-03-27	10-K	0001437749-26-010025
5	current assets	us-gaap:AssetsCurrent	\$140.5M	2025-12-31	2026-03-27	10-K	0001437749-26-010025
6	current liabilities	us-gaap:LiabilitiesCurrent	\$2.7M	2025-12-31	2026-03-27	10-K	0001437749-26-010025
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$89.5M	2025-12-31	2026-03-27	10-K	0001437749-26-010025
8	operating income	us-gaap:OperatingIncomeLoss	-\$16.7M	2025-12-31	2026-03-27	10-K	0001437749-26-010025
9	book equity	us-gaap:StockholdersEquity	\$137.8M	2025-12-31	2026-03-27	10-K	0001437749-26-010025
10	liabilities	us-gaap:Liabilities	\$2.9M	2025-12-31	2026-03-27	10-K	0001437749-26-010025
11	revenue	us-gaap:Revenues	\$0	2025-12-31	2026-03-27	10-K	0001437749-26-010025
12	revenue	us-gaap:Revenues	\$0	2024-12-31	2025-03-31	10-K	0001437749-25-009979
13	revenue	us-gaap:Revenues	\$0	2019-12-31	2020-03-27	10-K	0001654954-20-003363
14	revenue	us-gaap:Revenues	\$0	2018-12-31	2020-03-27	10-K	0001654954-20-003363
15	assets	us-gaap:Assets	\$7.3M	2023-12-31	2025-03-31	10-K	0001437749-25-009979
16	assets	us-gaap:Assets	\$13.2M	2022-12-31	2024-03-28	10-K	0001437749-24-009687
17	shares outstanding	dei:EntityCommonStockSharesOutstanding	6,692,140	2026-03-17	2026-04-01	10-K/A	0001437749-26-010841
18	shares outstanding	dei:EntityCommonStockSharesOutstanding	6,112,593	2025-03-14	2025-03-31	10-K	0001437749-25-009979